Login / Signup

Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy.

Kenichi InoueNorikazu MasudaHiroji IwataMasato TakahashiYoshinori ItoYasuo MiyoshiTakahiro NakayamaHirofumi MukaiJan-Stefan van der WaltJoji MoriSachi SakaguchiTsutomu KawaguchiYoshinori TanizawaAntonio Llombart-CussacGeorge W SledgeMasakazu Toi
Published in: Breast cancer (Tokyo, Japan) (2021)
NCT02107703; U.S. National Library of Medicine: https://clinicaltrials.gov/ct2/show/NCT02107703 .
Keyphrases